when

Latest
Archive

by source

All Sources
Sources Page

department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

by stage

Marketed
Phase 3
Phase 2
Phase 1
Preclinical

browse

Most catalysts
Recently active
All drugs →
Companies
Patent cliff

what

Trial readouts
PDUFA dates
Approvals
Earnings

when

Upcoming
Month grid
Recently passed

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Jobs
News
Drugs
Calendar
Companies

Hubs

Topics
Patent cliff
Publications
Readouts

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
search

GILEAD · news · pharmadog

← back to GILEAD

News mentioning GILEAD

192 stories

Jul 14, 26STAT+: Sales from controversial U.S. drug discount program rose to $100 billion last yearstat

Jul 14, 26STAT+: Pharmalittle: We’re reading about a battle between Lilly and Teva, psychedelic drugs, and morestat

Jul 13, 26STAT+: AIDS activists slam Biden R&D deal with Gilead over HIV prevention drug patentsstat

Jul 6, 26Novartis to acquire ADC developer in a deal worth up to $1.5Bbiopharma dive

Jul 6, 26The race for an Ebola therapy beginsstat

Jun 18, 26Biogen adds more immune drugs in $1B buyout of secretive startup RayTherabiopharma dive

Jun 11, 26STAT+: A suspicious denial pattern in Medicare Advantagestat

Jun 11, 26STAT+: Novartis doubles down on molecular glue strategystat

Jun 11, 26STAT+: Enliven Therapeutics’ leukemia drug shows promise in new studystat

Jun 11, 26STAT+: Private Medicare plans erect barriers to rehab care in pursuit of profit, federal investigators findstat

Jun 10, 26STAT+: Hope for Kendall Square’s lab marketstat

Jun 9, 26STAT+: Trump’s health care affordability czar takes aim at hospitalsstat

Jun 9, 26Diabetes Association in uproar after members expelled from annual meeting over protest of NIH cutsstat

Jun 9, 26FDA OKs first new sunscreen ingredient in more than 25 yearsstat

Jun 9, 26Merck, Gilead report mixed outcomes in key lung cancer, HIV studiesbiopharma dive

Jun 9, 26Gilead and Merck’s latest trial success and flopstat

Jun 9, 26Trodelvy misses in lung cancer, but Gilead and Merck have an HIV successendpoints

Jun 9, 26STAT+: Pharmalittle: We’re reading about a $10.6 billion GSK deal, an AstraZeneca obesity pill, and morestat

May 29, 26At ASCO, Merck makes case for a ‘cornerstone’ cancer drugbiopharma dive

May 29, 26Allogene CEO to step down; Agios drug fails key testbiopharma dive

May 29, 26STAT+: Pharmalittle: We’re reading about Replimune drug getting third try at FDA approval, a Pfizer deal in China, and morestat

May 29, 26Which vaccines will curb the Ebola outbreak? WHO debatesstat

May 28, 26GSK, Ionis unveil data for hepatitis B drug touted as ‘functional cure’biopharma dive

May 22, 26FDA Approves First Treatment for Chronic Hepatitis Delta Virus (HDV) Infectionfda press

May 18, 26Merck ADC, licensed from China, hits mark in first big global trialbiopharma dive

May 8, 26Post–T-DXd Sacituzumab Govitecan Plus Trastuzumab Yields Low ORR in HER2+ Metastatic Breast Canceronclive

May 8, 26Capivasertib/Fulvestrant Yields Numerical OS Advantage in PIK3CA/AKT1/PTEN–Altered Breast Canceronclive

May 8, 26Former FDA leaders, pharma speak out on mifepristonestat

May 8, 26The biotechs wear Pradastat

May 8, 26Lilly, Gilead lead pharma’s M&A boombiopharma dive

← prevpage 6 of 7next →